Sutro Biopharma Reports 85% Revenue Decline and Increased Losses in Latest Quarter

Sutro Biopharma, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenue of $9.8 million for the quarter, a stark decline of 85% compared to $63.7 million in the same period last year. For the first half of 2026, total revenue was $24.4 million, down 70% from $81.1 million in the first half of 2025. This decrease was primarily attributed to a $56.4 million reduction in revenue from Ipsen Pharma, which included the derecognition of $53.2 million in deferred revenue following Ipsen's decision not to advance the STRO-003 program.

Operating expenses for Sutro Biopharma also saw a notable reduction, totaling $39.7 million for the second quarter, down 41% from $67.1 million a year earlier. The decrease was driven by lower research and development costs, which fell to $31.7 million from $38.3 million, and a significant drop in restructuring costs, which were reduced to $0.2 million from $18.4 million. Despite these reductions, the company reported a loss from operations of $29.9 million for the quarter, compared to a loss of $3.3 million in the prior year, reflecting a substantial increase in net loss to $38.5 million from $11.5 million.

Strategically, Sutro Biopharma has undergone significant restructuring efforts, including a workforce reduction of approximately two-thirds since March 2025, aimed at prioritizing its three preclinical programs: STRO-004, STRO-006, and STRO-227. The company has also shifted to an external manufacturing strategy, ceasing operations at its San Carlos facility. These changes are part of a broader effort to streamline operations and extend its cash runway, as the company continues to face substantial losses and negative cash flows.

As of June 30, 2026, Sutro Biopharma reported an accumulated deficit of $1.1 billion and cash, cash equivalents, and marketable securities totaling $164.3 million. The company anticipates needing additional capital to support ongoing research and development activities. In February 2026, Sutro raised approximately $110 million through a public offering, which is expected to help fund its operations for at least the next 12 months. However, the company cautioned that it may need to raise further capital through various means, including equity offerings or collaborations, to continue its development efforts.

Looking ahead, Sutro Biopharma is focused on advancing its clinical programs, particularly STRO-004, which is currently in a Phase 1 trial. The company has reported encouraging early clinical activity and plans to provide further updates in the first half of 2027. However, the ongoing need for additional funding and the inherent risks associated with drug development remain significant challenges for the company as it seeks to navigate its path forward in the competitive oncology market.